226 related articles for article (PubMed ID: 8883418)
41. Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors.
Christian JA; Huddart RA; Norman A; Mason M; Fossa S; Aass N; Nicholl EJ; Dearnaley DP; Horwich A
J Clin Oncol; 2003 Mar; 21(5):871-7. PubMed ID: 12610187
[TBL] [Abstract][Full Text] [Related]
42. [Treatment outcome of children and adolescents with germ cell tumor after combined therapy---a report of 44 cases].
Sun XF; Yang QY; Zhen ZJ; Xia Y; Huang ZH; Ling JY
Ai Zheng; 2006 Dec; 25(12):1529-32. PubMed ID: 17166380
[TBL] [Abstract][Full Text] [Related]
43. [Urologic treatment of testicular germ cell cancer].
Fernández Gómez JM; Escaf Barmadah S; Guate Ortiz JL; Martín Huescar A; Fresno Forcelledo F; García Rodríguez J; Rodríguez Faba O; Jalón Monzón A; Rodríguez Martínez JJ
Arch Esp Urol; 2002 Oct; 55(8):927-36. PubMed ID: 12455283
[TBL] [Abstract][Full Text] [Related]
44. Extragonadal germ cell tumor: a clinical study.
Bassetto MA; Pasini F; Franceschi T; Mustacchi G; Cetto GL
Anticancer Res; 1995; 15(6B):2751-4. PubMed ID: 8669858
[TBL] [Abstract][Full Text] [Related]
45. Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation.
Zschäbitz S; Lasitschka F; Hadaschik B; Hofheinz RD; Jentsch-Ullrich K; Grüner M; Jäger D; Grüllich C
Eur J Cancer; 2017 May; 76():1-7. PubMed ID: 28262583
[TBL] [Abstract][Full Text] [Related]
46. Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumors: a phase II study.
Mardiak J; Sálek T; Sycová-Milá Z; Obertová J; Hlavatá Z; Mego M; Recková M; Koza I
Neoplasma; 2005; 52(6):497-501. PubMed ID: 16284696
[TBL] [Abstract][Full Text] [Related]
47. Advanced seminoma--treatment results and prognostic factors for survival after first-line, cisplatin-based chemotherapy and for patients with recurrent disease: a single-institution experience in 145 patients.
Gholam D; Fizazi K; Terrier-Lacombe MJ; Jan P; Culine S; Theodore C
Cancer; 2003 Aug; 98(4):745-52. PubMed ID: 12910518
[TBL] [Abstract][Full Text] [Related]
48. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial.
Loehrer PJ; Johnson D; Elson P; Einhorn LH; Trump D
J Clin Oncol; 1995 Feb; 13(2):470-6. PubMed ID: 7531223
[TBL] [Abstract][Full Text] [Related]
49. Surveillance for stage I testicular germ cell tumours: results and cost benefit analysis of management options.
Francis R; Bower M; Brunström G; Holden L; Newlands ES; Rustin GJ; Seckl MJ
Eur J Cancer; 2000 Oct; 36(15):1925-32. PubMed ID: 11000572
[TBL] [Abstract][Full Text] [Related]
50. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors.
Böhlen D; Borner M; Sonntag RW; Fey MF; Studer UE
J Urol; 1999 Apr; 161(4):1148-52. PubMed ID: 10081858
[TBL] [Abstract][Full Text] [Related]
51. Long-term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy.
Beyer J; Kingreen D; Krause M; Schleicher J; Schwaner I; Schwella N; Huhn D; Siegert W
Cancer; 1997 Jan; 79(1):161-8. PubMed ID: 8988741
[TBL] [Abstract][Full Text] [Related]
52. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study.
Kaye SB; Mead GM; Fossa S; Cullen M; deWit R; Bodrogi I; van Groeningen C; Sylvester R; Collette L; Stenning S; De Prijck L; Lallemand E; deMulder P
J Clin Oncol; 1998 Feb; 16(2):692-701. PubMed ID: 9469359
[TBL] [Abstract][Full Text] [Related]
53. Advances in the management of non-seminomatous germ cell tumors during the cisplatin era: a single-institution experience.
Muramaki M; Hara I; Miyake H; Yamada Y; Kawabata G; Kamidono S
Int J Urol; 2004 Sep; 11(9):768-73. PubMed ID: 15379942
[TBL] [Abstract][Full Text] [Related]
54. Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma.
Ganjoo KN; Chan RJ; Sharma M; Einhorn LH
J Clin Oncol; 1999 Nov; 17(11):3457-60. PubMed ID: 10550142
[TBL] [Abstract][Full Text] [Related]
55. Outcome analysis after post-chemotherapy surgery in patients with non-seminomatous germ cell tumours.
Gerl A; Clemm C; Schmeller N; Dienemann H; Lamerz R; Kriegmair M; Wilmanns W
Ann Oncol; 1995 May; 6(5):483-8. PubMed ID: 7545430
[TBL] [Abstract][Full Text] [Related]
56. Risk-adapted chemotherapy of germ cell tumors with carboplatin, etoposide and bleomycin for low-risk and cisplatin, etoposide and ifosfamide for high-risk patients. A single-center study.
Tscherry G; Jacky E; Jost LM; Stahel RA
Oncology; 2000 Aug; 59(2):110-7. PubMed ID: 10971168
[TBL] [Abstract][Full Text] [Related]
57. [Bilateral and synchronous testicular teratoma: a case report and literature review].
Matabuena-Tamez P; Canepa-Fernández P; Valencia-García LC; Gutiérrez-Samperio C; Gallegos-Corona MA
Cir Cir; 2015; 83(6):527-31. PubMed ID: 26164135
[TBL] [Abstract][Full Text] [Related]
58. First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial.
Bokemeyer C; Schleucher N; Metzner B; Thomas M; Rick O; Schmoll HJ; Kollmannsberger C; Boehlke I; Kanz L; Hartmann JT
Br J Cancer; 2003 Jul; 89(1):29-35. PubMed ID: 12838296
[TBL] [Abstract][Full Text] [Related]
59. POMB/ACE chemotherapy in non-seminomatous germ cell tumours: outcome and importance of dose intensity.
Husband DJ; Green JA
Eur J Cancer; 1992; 28(1):86-91. PubMed ID: 1373636
[TBL] [Abstract][Full Text] [Related]
60. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group.
Bokemeyer C; Harstrick A; Beyer J; Metzner B; Rüther U; Hartmann JT; Holstein K; Derigs HG; de Wit R; Casper J; Schöffski P; Kührer I; Illiger HJ; Kempf B; Reichle A; Föller A; Hossfeld DK; Fischer JT; Berdel WE; Gerhartz HH; Kirchner H; Pflüger KH; Ostermann H; Kanz L; Schmoll HJ
Semin Oncol; 1998 Apr; 25(2 Suppl 4):24-32; discussion 45-8. PubMed ID: 9578059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]